Recent News

• 07.23.2025 - Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
• 06.16.2025 - Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
• 05.19.2025 - Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
• 05.13.2025 - Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
• 05.08.2025 - Alzamend Neuro Announces Reverse Stock Split
• 05.07.2025 - Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
• 03.25.2025 - Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital

Recent Filings

• 07.22.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 07.11.2025 - 144/A Report of proposed sale of securities
• 07.09.2025 - 8-K Current report
• 05.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.09.2025 - 144 Report of proposed sale of securities
• 05.08.2025 - 8-K Current report
• 05.08.2025 - EX-99.1 EX-99.1
• 04.25.2025 - 8-K Current report
• 04.09.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 04.08.2025 - EFFECT Notice of Effectiveness